Acalabrutinib, marketed under the brand name Calquence, is a medication primarily used to treat certain types of cancers. It is a second-generation Bruton Tyrosine Kinase (BTK) inhibitor, designed to interfere with the BTK signaling pathway, which plays a crucial role in the growth and survival of cancer cells.
